Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246660 · ClinicalTrials.gov registry record · NA
RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT02246660: Completed NA study, sponsored by Northwestern University.
NCT02246660 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246660, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The RESTORE trial will determine whether resveratrol supplementation can improve walking performance in older people with lower extremity peripheral arterial disease (PAD). Resveratrol, a polyphenol and natural supplement, specifically targets several impairments associated with walking difficulty and mobility loss in people with PAD.
Primary Outcome
Six month changes in 6-Minute Walk Distance (meters) in response to resveratrol therapy in patients with Peripheral Artery Disease were measured.
Interventions
- DRUG Placebo
- DRUG Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT02246660 record still lists
NCT02246660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02246660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02246660 about?
NCT02246660 is a clinical study titled "RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)". The RESTORE trial will determine whether resveratrol supplementation can improve walking performance in older people with lower extremity peripheral arterial disease (PAD). Resveratrol, a polyphenol and natural supplement, specifically targets several impairments associated with walking difficulty a...
What is the current status of trial NCT02246660?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2015-01. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02246660?
The interventions under investigation include: Placebo (DRUG), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT02246660?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02246660's enrollment target sits among peer trials
66 1139th of 2000 higher than 857 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia